{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:28:39Z","timestamp":1793726919059,"version":"4.6.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"am","delay-in-days":291,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015537","name":"Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS113828"],"award-info":[{"award-number":["R01NS113828"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["K23NS117883"],"award-info":[{"award-number":["K23NS117883"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30 EY 026877"],"award-info":[{"award-number":["P30 EY 026877"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ajo.2023.02.013","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T19:10:25Z","timestamp":1677006625000},"page":"213-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["Visual Outcomes Following Plasma Exchange for Optic Neuritis: An International Multicenter Retrospective Analysis of 395 Optic Neuritis Attacks"],"prefix":"10.1016","volume":"252","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3644-7528","authenticated-orcid":false,"given":"John J.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin P.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole Caroline","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanthaya","family":"Tisavipat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Tariq","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Chodnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deena A.","family":"Tajfirouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Jamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Kunchok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"Eggenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie A. Di","family":"Nome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias S.","family":"Sotirchos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni S.","family":"Vasileiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda D.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather E.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia Elizabeth Villarreal","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanyatuth","family":"Padungkiatsagul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Stiebel-Kalish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itay","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Wilf-Yarkoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Danesh-Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Ivanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saif","family":"Huda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirasol","family":"Forcadela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hodge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Poullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Rode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Papeix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Saheb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Boudot de la Motte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Vignal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Hacohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Pique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Maillart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Deschamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Audoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Marignier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2023.02.013_bib0001","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","article-title":"Optic neuritis","volume":"13","author":"Toosy","year":"2014","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.ajo.2023.02.013_bib0002","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1474-4422(22)00187-9","article-title":"Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment","volume":"22","author":"Bennett","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0003","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group","volume":"326","author":"Beck","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajo.2023.02.013_bib0004","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.survophthal.2019.08.001","article-title":"Optic neuritis in the era of biomarkers","volume":"65","author":"Chen","year":"2020","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0005","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2023.02.013_bib0006","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.ajo.2023.02.013_bib0007","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/WNO.0000000000000700","article-title":"Acute management of optic neuritis: an evolving paradigm","volume":"38","author":"Horton","year":"2018","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0008","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0009","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00415-016-8073-8","article-title":"Plasma exchange response in 34 patients with severe optic neuritis","volume":"263","author":"Deschamps","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0010","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1212\/01.WNL.0000138437.99046.6B","article-title":"Plasma exchange for severe optic neuritis: treatment of 10 patients","volume":"63","author":"Ruprecht","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ajo.2023.02.013_bib0011","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420947977","article-title":"Vision improvement in severe acute isolated optic neuritis after plasma exchange treatment in Chinese population: a prospective case series study","volume":"13","author":"Tan","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.ajo.2023.02.013_bib0012","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1600-0404.2011.01612.x","article-title":"Treatment of steroid-unresponsive optic neuritis with plasma exchange","volume":"126","author":"Roesner","year":"2012","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.ajo.2023.02.013_bib0013","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/archophthalmol.2012.1126","article-title":"Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica","volume":"130","author":"Merle","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0014","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1007\/s10792-019-01090-z","article-title":"Plasma exchange: an effective add-on treatment of optic neuritis in neuromyelitis optica spectrum disorders","volume":"39","author":"Song","year":"2019","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0015","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10384-018-0602-9","article-title":"Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders","volume":"62","author":"Mori","year":"2018","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0016","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ajo.2023.02.013_bib0017","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1159\/000504027","article-title":"Visual outcomes of plasma exchange treatment of steroid-refractory optic neuritis: a retrospective monocentric analysis","volume":"46","author":"Skorupka","year":"2019","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.ajo.2023.02.013_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104020","article-title":"Treatment outcomes of first-ever episode of severe optic neuritis","volume":"66","author":"Galetta","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ajo.2023.02.013_bib0019","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1177\/11206721211065218","article-title":"Efficacy and safety of plasma exchange or immunoadsorption for the treatment of option neuritis in demyelinating diseases: a systematic review and meta-analysis","volume":"32","author":"Zhang","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.ajo.2023.02.013_bib0021","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"Lopez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0022","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0023","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00417-008-0926-0","article-title":"Resolving the clinical acuity categories \"hand motion\" and \"counting fingers\" using the Freiburg Visual Acuity Test (FrACT)","volume":"247","author":"Lange","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0024","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.ophtha.2005.01.036","article-title":"Poor prognosis of visual outcome after visual loss from giant cell arteritis","volume":"112","author":"Danesh-Meyer","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2023.02.013_bib0025","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.0b013e3181b879be","article-title":"Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months","volume":"73","author":"Llufriu","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.ajo.2023.02.013_bib0026","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.58.1.143","article-title":"Plasma exchange for severe attacks of CNS demyelination: predictors of response","volume":"58","author":"Keegan","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.ajo.2023.02.013_bib0027","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.ajo.2023.02.013_bib0028","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1111\/1744-9987.13844","article-title":"Therapeutic plasma exchange for optic neuritis attacks in patients with neuromyelitis optica spectrum disorders","volume":"26","author":"Gonzalez","year":"2022","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.ajo.2023.02.013_bib0029","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/00001756-200205240-00001","article-title":"Ageing and CNS remyelination","volume":"13","author":"Franklin","year":"2002","journal-title":"Neuroreport"},{"key":"10.1016\/j.ajo.2023.02.013_bib0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0031","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/WCO.0000000000000766","article-title":"Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis","volume":"33","author":"Chen","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0032","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.ajo.2023.02.013_bib0033","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00415-017-8651-4","article-title":"Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China","volume":"265","author":"Zhao","year":"2018","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.ajo.2023.02.013_bib0034","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/bjophthalmol-2017-311177","article-title":"Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients","volume":"102","author":"Zhao","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0035","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jns.2018.11.029","article-title":"The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis","volume":"396","author":"Liu","year":"2019","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.ajo.2023.02.013_bib0036","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/ene.14089","article-title":"Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients","volume":"27","author":"Shor","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103222","article-title":"Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease","volume":"56","author":"Akaishi","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ajo.2023.02.013_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.540156","article-title":"AQP4-IgG and MOG-IgG related optic neuritis-prevalence, optical coherence tomography findings, and visual outcomes: a systematic review and meta-analysis","volume":"11","author":"Filippatou","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170847","article-title":"Retinal nerve fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study","volume":"12","author":"Stiebel-Kalish","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ajo.2023.02.013_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104237","article-title":"Details and outcomes of a large cohort of MOG-IgG associated optic neuritis","volume":"68","author":"Chen","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ajo.2023.02.013_bib0041","article-title":"Recovery of vision in myelin oligodendrocyte glycoprotein-IgG optic neuritis without treatment: a case series","author":"Vosoughi","year":"2022","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0042","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ophtha.2006.06.060","article-title":"Natural history of the visual impairment of relapsing neuromyelitis optica","volume":"114","author":"Merle","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2023.02.013_bib0043","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1001\/archophthalmol.2007.26","article-title":"Clinical course of optic neuritis in patients with relapsing neuromyelitis optica","volume":"126","author":"Papais-Alvarenga","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0044","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/WNO.0b013e31823a9ebc","article-title":"Comparison of visual acuity and automated perimetry findings in patients with neuromyelitis optica or multiple sclerosis after single or multiple attacks of optic neuritis","volume":"32","author":"Fernandes","year":"2012","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0045","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jns.2010.07.011","article-title":"Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis","volume":"298","author":"Jarius","year":"2010","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.ajo.2023.02.013_bib0046","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1007\/s00415-016-8155-7","article-title":"Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages","volume":"263","author":"Zhou","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0047","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1177\/1352458519864928","article-title":"Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning","volume":"26","author":"Sotirchos","year":"2020","journal-title":"Mult Scler"},{"key":"10.1016\/j.ajo.2023.02.013_bib0048","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1007\/s00415-015-7844-y","article-title":"Features of anti-aquaporin 4 antibody-seropositive Chinese patients with neuromyelitis optica spectrum optic neuritis","volume":"262","author":"Li","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0049","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.ajo.2023.02.013_bib0050","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/acn3.51203","article-title":"Effect of plasma exchange in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"7","author":"Kosiyakul","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0051","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ajo.2023.02.013_bib0052","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40120-022-00344-w","article-title":"Efficacy of plasma exchange treatment for demyelinating optic neuritis associated with various serum antibodies: a prospective cohort study","volume":"11","author":"Fu","year":"2022","journal-title":"Neurol Ther"},{"key":"10.1016\/j.ajo.2023.02.013_bib0053","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajo.2020.07.014","article-title":"Population-based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies","volume":"220","author":"Hassan","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2023.02.013_bib0054","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0055","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1212\/01.WNL.0000094316.90240.EB","article-title":"Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000","volume":"61","author":"Mayr","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ajo.2023.02.013_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102709","article-title":"Timing of plasma exchange for neuromyelitis optica spectrum disorders: a meta-analysis","volume":"48","author":"Huang","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"10.1016\/j.ajo.2023.02.013_bib0057","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3390\/jcm9051597","article-title":"Plasma exchange or immunoadsorption in demyelinating diseases: a meta-analysis","volume":"9","author":"Lipphardt","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.ajo.2023.02.013_bib0058","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1472-6963-11-101","article-title":"Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barre syndrome","volume":"11","author":"Winters","year":"2011","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.ajo.2023.02.013_bib0059","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1017\/S0317167100034053","article-title":"Cost analysis of methylprednisolone treatment of multiple sclerosis patients","volume":"25","author":"Robson","year":"1998","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.ajo.2023.02.013_bib0060","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.ophtha.2013.01.068","article-title":"The economic burden of vision loss and eye disorders among the United States population younger than 40 years","volume":"120","author":"Wittenborn","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2023.02.013_bib0061","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/archopht.1988.01060140207023","article-title":"The Optic Neuritis Treatment Trial","volume":"106","author":"Beck","year":"1988","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0062","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/WNO.0000000000000197","article-title":"Should plasma exchange be offered to patients with multiple sclerosis-associated optic neuritis?","volume":"35","author":"Pula","year":"2015","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0063","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/jca.20143","article-title":"Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures","volume":"22","author":"Shemin","year":"2007","journal-title":"J Clin Apher"},{"key":"10.1016\/j.ajo.2023.02.013_bib0064","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2023.02.013_bib0065","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajo.2023.02.013_bib0066","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ajo.2023.02.013_bib0067","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.msard.2015.07.017","article-title":"Placebo controlled trials in neuromyelitis optica are needed and ethical","volume":"4","author":"Cree","year":"2015","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.ajo.2023.02.013_bib0068","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamaophthalmol.2017.6757","article-title":"Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the Optic Neuritis Treatment Trial","volume":"136","author":"Chen","year":"2018","journal-title":"JAMA Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939423000661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939423000661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T21:02:37Z","timestamp":1777410157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939423000661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":68,"alternative-id":["S0002939423000661"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2023.02.013","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Visual Outcomes Following Plasma Exchange for Optic Neuritis: An International Multicenter Retrospective Analysis of 395 Optic Neuritis Attacks","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2023.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}